Fusions NTRK : une nouvelle piste dans les cancers digestifs ?

Ouali, Kaïssa; Pellat, Anna; Cohen, Romain; Svrcek, Magali; Penault‐Llorca, Frédérique; Thewis, André

doi:10.1016/j.bulcan.2019.11.014

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are three classes of TRK receptors, TRKA, TRKB and TRKC, encoded by three genes, Neurotrophic Tropomyosin Receptor Kinase 1 to 3 (NTRK1, NTRK2 and NTRK3), respectively. For several years now, fusions between the 3′ part of the NTRK gene and the 5′ part of another gene have been described, resulting in the formation of a TRK fusion protein responsible for the constitutional activation of the receptor and pro-oncogenic phosphorylation cascades responsible for the development of numerous cancers [ 54 ].…”

Section: Introductionmentioning

confidence: 99%

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments

Valery,

Vasseur,

Fachinetti

et al. 2023

Cancers

View full text Add to dashboard Cite

Biliary tract cancers (BTCs) are rare tumours, most often diagnosed at an unresectable stage, associated with poor prognosis, with a 5-year survival rate not exceeding 10%. Only first- and second-line treatments are well codified with the combination of cisplatin-gemcitabine chemotherapy and immunotherapy followed by 5-FU and oxaliplatin chemotherapy, respectively. Many studies have shown that BTC, and more particularly intrahepatic cholangiocarcinoma (iCCA), have a high rate of targetable somatic alteration. To date, the FDA has approved several drugs. Ivosidenib targeting IDH1 mutations, as well as futibatinib and pemigatinib targeting FGFR2 fusions, are approved for pre-treated advanced CCA. The combination of dabrafenib and trametinib are approved for BRAFV600E mutated advanced tumours, NTRK inhibitors entrectinib and larotrectinib for tumours bearing NTRK fusion and prembrolizumab for MSI-H advanced tumours, involving a small percentage of BTC in these three settings. Several other potentially targetable alterations are found in BTC, such as HER2 mutations or amplifications or KRASG12C mutations and mutations in genes involved in DNA repair mechanisms. This review aims to clarify the specific diagnostic modalities for gene alterations and to summarize the results of the main trials and developments underway for the management of advanced BTC with targetable alterations.

show abstract

Section: Introductionmentioning

confidence: 99%